50.69
price up icon0.96%   0.48
after-market 시간 외 거래: 52.06 1.37 +2.70%
loading

Protagonist Therapeutics Inc 주식(PTGX)의 최신 뉴스

pulisher
Jun 18, 2025

10 Biotech Stocks Screaming a Buy - Insider Monkey

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Protagonist Therapeutics’ SWOT analysis: biotech stock poised for growth - Investing.com

Jun 18, 2025
pulisher
Jun 17, 2025

BIOTECHNOLOGY VALUE FUND L P's Strategic Acquisition in Protagonist Therapeutics Inc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Coverage on Protagonist Therapeutics (PTGX) with a 'Buy' Rating | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $7 - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Citigroup Initiates Protagonist Therapeutics at Buy With $72 Price Target - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Protagonist Therapeutics (PTGX) Initiated at Buy by Citi with $72 Target | PTGX Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 16, 2025

How To Trade (PTGX) - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Jun 16, 2025
pulisher
Jun 16, 2025

GAMMA Investing LLC Raises Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Jun 16, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Sells $570,300.00 in Stock - MarketBeat

Jun 14, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com Canada

Jun 14, 2025
pulisher
Jun 14, 2025

Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Subdued Growth No Barrier To Protagonist Therapeutics, Inc. (NASDAQ:PTGX) With Shares Advancing 27% - simplywall.st

Jun 13, 2025
pulisher
Jun 11, 2025

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 - The Columbus Dispatch

Jun 11, 2025
pulisher
Jun 11, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Hold at Wall Street Zen - MarketBeat

Jun 11, 2025
pulisher
Jun 10, 2025

Hennion & Walsh Asset Management Inc. Has $1.26 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

Jun 10, 2025
pulisher
Jun 09, 2025

California State Teachers Retirement System Sells 316 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Upgraded to “Hold” at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga

Jun 06, 2025
pulisher
Jun 05, 2025

Exploring Three High Growth Tech Stocks In The US Market - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

(PTGX) Long Term Investment Analysis - news.stocktradersdaily.com

Jun 04, 2025
pulisher
Jun 04, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Cut to "Sell" at Wall Street Zen - MarketBeat

Jun 04, 2025
pulisher
Jun 04, 2025

Protagonist Therapeutics’ (PTGX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright reaffirms Buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
Jun 03, 2025

BTIG maintains buy rating on Protagonist Therapeutics stock By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
Jun 03, 2025

Protagonist Therapeutics (PTGX) Rating and Price Target Reaffirmed | PTGX Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 02, 2025

Protagonist Therapeutics: Promising Future with Rusfertide as a Standard of Care for Polycythemia Vera - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

ASCO 2025: Protagonist-Takeda, Novartis post phase III wins - BioWorld MedTech

Jun 02, 2025
pulisher
Jun 02, 2025

Transcript : Protagonist Therapeutics, Inc.Special Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Protagonist Therapeutics, Inc. and Takeda Announce Asco Plenary Presentation Highlighting Full 32-Week Results from Phase 3 Verify Study of Rusfertide - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Protagonist Therapeutics, Takeda's Potential Polycythemia Vera Drug Meets Primary Endpoint - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Protagonist Therapeutics (PTGX): Promising Phase 3 Results for R - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

Protagonist Therapeutics (PTGX): Promising Phase 3 Results for Rusfertide | PTGX Stock News - GuruFocus

Jun 01, 2025
pulisher
Jun 01, 2025

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera - Quantisnow

Jun 01, 2025
pulisher
May 31, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street Zen - Defense World

May 31, 2025
pulisher
May 29, 2025

Cache Advisors LLC Makes New $392,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat

May 29, 2025
pulisher
May 28, 2025

Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome - MSN

May 28, 2025
pulisher
May 28, 2025

D. E. Shaw & Co. Inc. Sells 21,121 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

May 28, 2025
pulisher
May 28, 2025

Bank of America Corp DE Has $5.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

May 28, 2025
pulisher
May 27, 2025

Protagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancements - Investing.com India

May 27, 2025
pulisher
May 25, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Reduced by Ameriprise Financial Inc. - Defense World

May 25, 2025
pulisher
May 24, 2025

Protagonist Therapeutics' (PTGX) Buy Rating Reiterated at HC Wainwright - MarketBeat

May 24, 2025
pulisher
May 23, 2025

BNP Paribas Financial Markets Has $751,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World

May 23, 2025
pulisher
May 23, 2025

Protagonist Therapeutics earnings missed by $0.13, revenue fell short of estimates - Investing.com Canada

May 23, 2025
pulisher
May 21, 2025

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025 | PTGX Stock News - GuruFocus

May 21, 2025
pulisher
May 21, 2025

Exclusive: Protagonist Therapeutics CEO Reveals Company Strategy at Major Jefferies Healthcare Conference - Stock Titan

May 21, 2025
pulisher
May 20, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of “Buy” from Analysts - Defense World

May 20, 2025
pulisher
May 20, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Given “Buy” Rating at HC Wainwright - Defense World

May 20, 2025
pulisher
May 19, 2025

PTGX: HC Wainwright & Co. Reiterates Buy Rating with $80 Target | PTGX Stock News - GuruFocus

May 19, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):